Theriva Biologics, Inc. (TOVX) - Form 8-K Summary
Business Context and Reporting Period
Theriva Biologics, Inc., a Nevada corporation, filed this Current Report on Form 8-K on August 13, 2024. The filing serves to disseminate financial information regarding the quarter ended June 30, 2024, via a press release attached as Exhibit 99.1.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained within the attached press release (Exhibit 99.1) but are not detailed in the body of this 8-K document.
Material Changes
No specific material changes versus the prior comparable period are quantified in this filing text. The document solely announces the issuance of the press release containing the quarterly results.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in Item 2.02 and the attached press release shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into any other SEC filings. No specific guidance, outlook, or risk factors are detailed in the text of this report.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 13, 2024) for actual financial figures for the quarter ended June 30, 2024.
- Verify the company's cash position and runway given the lack of specific liquidity data in this summary document.
- Confirm the trading status of Common Stock (TOVX) on NYSE American.
- Check for any subsequent filings that may incorporate the press release data by reference.